These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
405 related items for PubMed ID: 23197596
1. Detection rates of precancerous and cancerous cervical lesions within one screening round of primary human papillomavirus DNA testing: prospective randomised trial in Finland. Leinonen MK, Nieminen P, Lönnberg S, Malila N, Hakama M, Pokhrel A, Laurila P, Tarkkanen J, Anttila A. BMJ; 2012 Nov 29; 345():e7789. PubMed ID: 23197596 [Abstract] [Full Text] [Related]
2. Rate of cervical cancer, severe intraepithelial neoplasia, and adenocarcinoma in situ in primary HPV DNA screening with cytology triage: randomised study within organised screening programme. Anttila A, Kotaniemi-Talonen L, Leinonen M, Hakama M, Laurila P, Tarkkanen J, Malila N, Nieminen P. BMJ; 2010 Apr 27; 340():c1804. PubMed ID: 20423964 [Abstract] [Full Text] [Related]
3. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds. C Kitchener H, Canfell K, Gilham C, Sargent A, Roberts C, Desai M, Peto J. Health Technol Assess; 2014 Apr 27; 18(23):1-196. PubMed ID: 24762804 [Abstract] [Full Text] [Related]
4. Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting. Leinonen M, Nieminen P, Kotaniemi-Talonen L, Malila N, Tarkkanen J, Laurila P, Anttila A. J Natl Cancer Inst; 2009 Dec 02; 101(23):1612-23. PubMed ID: 19903804 [Abstract] [Full Text] [Related]
5. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Rijkaart DC, Berkhof J, Rozendaal L, van Kemenade FJ, Bulkmans NW, Heideman DA, Kenter GG, Cuzick J, Snijders PJ, Meijer CJ. Lancet Oncol; 2012 Jan 02; 13(1):78-88. PubMed ID: 22177579 [Abstract] [Full Text] [Related]
13. [Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors]. Ronco G, Biggeri A, Confortini M, Naldoni C, Segnan N, Sideri M, Zappa M, Zorzi M, Calvia M, Accetta G, Giordano L, Cogo C, Carozzi F, Gillio Tos A, Arbyn M, Mejier CJ, Snijders PJ, Cuzick J, Giorgi Rossi P. Epidemiol Prev; 2012 Jan 02; 36(3-4 Suppl 1):e1-72. PubMed ID: 22828243 [Abstract] [Full Text] [Related]
16. Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial. Canfell K, Caruana M, Gebski V, Darlington-Brown J, Heley S, Brotherton J, Gertig D, Jennett CJ, Farnsworth A, Tan J, Wrede CD, Castle PE, Saville M. PLoS Med; 2017 Sep 02; 14(9):e1002388. PubMed ID: 28926579 [Abstract] [Full Text] [Related]
20. Primary cervical cancer screening with HPV testing compared with liquid-based cytology: results of round 1 of a randomised controlled trial -- the HPV FOCAL Study. Ogilvie GS, Krajden M, van Niekerk DJ, Martin RE, Ehlen TG, Ceballos K, Smith LW, Kan L, Cook DA, Peacock S, Stuart GC, Franco EL, Coldman AJ. Br J Cancer; 2012 Dec 04; 107(12):1917-24. PubMed ID: 23169286 [Abstract] [Full Text] [Related] Page: [Next] [New Search]